1. Cost-Utility Analysis of Depot Atypical Antipsychotics for Chronic Schizophrenia in Croatia 
Vlado Jukic, MD, PhD, Miro Jakovljevic, MD, PhD, Igor Filipcic, MD, PhD, Miroslav Herceg, MD, PhD, Ante Silic, MD, PhD, Tatjana Tomljanovic, MD, Roman Zilbershtein, MSc, Rasmus C.D. Jensen, MSc, Michiel E.H. Hemels, MSc, MBA, Thomas R. Einarson, PhD 
Value in Health Regional Issues 
Volume 2, Issue 2, Pages (September 2013)
DOI: /j.vhri
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Model used for the pharmacoeconomic analysis. LAI, long-acting injectable; OLZ-LAI, olanzapine pamoate long-acting injectable; PP-LAI, paliperidone palmitate long-acting injectable.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Cloud diagram from the probabilistic sensitivity analysis comparing incremental costs (Y axis) and QALYs (X axis) between (A) PP-LAI and RIS-LAI and (B) PP-LAI and OLZ-LAI. OLZ-LAI, olanzapine pamoate long-acting injectable; PP-LAI, paliperidone palmitate long-acting injectable; QALY, quality-adjusted life-year; RIS-LAI, risperidone long-acting injectable.
Value in Health Regional Issues 2013 2, DOI: ( /j.vhri )
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions